- Merck, Lundbeck terminate sleep drug license deal
- Pfizer, Neurocrine end agreement for indiplon
- Neurocrine licenses sleep drug from DOV
- Forest will market Lundbeck's antidepressant in the US
- Merck, Acumen R&D Alzheimer's therapeutics; terminated
- Merck & Co., Actelion in CHF350mm cardio-renal alliance; terminated
- Merck, Neurogen sign alliance to develop pain therapeutics; terminated
- Merck, Schering-Plough develop cholesterol, respiratory drugs
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.